详情
The CEO Health Premium: Obesity Signals and Asset Pricing
This paper documents that the physical appearance of CEOs, specifically excess body
weight, is priced in the capital market. In the absence of explicit health disclosures,market participants interpret obesity as a proxy for latent health risks and potential managerial disrupts, thereby demanding a compensation premium. Our analysis reveals that (1) IPOs of firms with obese CEOs have lower first-day performance, (2) these firms achieve a lower valuation, (3) the stocks of these firms have lower liquidity and (4) they provide higher stock returns thereafter. A quasi-natural experiment based on the invention of anti-obesity medications provides supporting causal evidence.